The calcium-sensing receptor (CSR) is a G-protein receptor that plays a critical role in calcium regulation. In the kidney, the CSR regulates calcium reabsorption in the thick ascending limb, where stimulation of the CSR inhibits calcium reabsorption in response to increased calcium in the peritubular fluid. In the collecting duct, apical CSR activation may play a role in osmoregulation, increasing water excretion in response to increased luminal calcium. Methods: We studied the ontogeny of the CSR in developing human kidney using immunohistochemical methods. results: The CSR is first expressed in the S-shaped body in the region destined to form the ascending limb and distal tubule. Other regions of the S-shaped body, as well as ureteric buds, do not express the CSR. The CSR is observed in thick ascending limb as early as 20 wk of development. The CSR is not observed in proximal tubule or collecting duct between 20 and 40 wk of human development. conclusion: During early human renal development, CSR expression is limited to the thick ascending limb and distal tubule, where this receptor may play a role in calcium homeostasis between 20 and 40 wk of human development.
P
remature birth imposes stress on the kidney during a critical period of nephron formation and differentiation. The renal consequences of prematurity include impaired skeletal development due to abnormal renal calcium and phosphorus homeostasis (1); nephrocalcinosis; renal accumulation of calcium oxalate, which may lead to abnormal tubular function in childhood (2-10); and impaired nephron formation, leading to abnormal renal function in adulthood (11, 12) .
The calcium-sensing receptor (CSR) is a G-proteincoupled receptor expressed mainly in parathyroid, calcitonin-secreting cells of the thyroid, bone, intestine, and kidney. The CSR detects changes in serum calcium and directly or indirectly helps normalize serum calcium level (13) . Approximately 25% of calcium reabsorption occurs in the thick ascending limb (TAL) of the loop of Henle, where tubular fluid becomes electropositive relative to peritubular fluid, and calcium moves via paracellular pathways to the electronegative peritubular space (14, 15) . The CSR, expressed along the basolateral portion of the TAL, senses increased peritubular calcium and inhibits calcium reabsorption via downregulation of the apical renal outer medullary potassium channel, dissipating the charge gradient required for calcium reabsorption, or via inhibition of vasopressininduced cAMP formation, which may affect permeability of the paracellular pathway (16) . The critical importance of the CSR in renal calcium regulation is seen in patients with familial hypocalciuric hypercalcemia, in whom downregulating mutations of the CSR impair the ability of the CSR to respond to rising peritubular calcium levels, resulting in continued calcium absorption in the face of increased serum calcium (17) .
It has been suggested that, in the mature collecting duct (CD), the CSR may play a role in preventing kidney stone formation by increasing water excretion in response to increased concentration of luminal calcium, leading to a decrease in urine calcium concentration (18) . The CSR has been implicated in the pathogenesis of polyuria associated with hypercalcemia via this mechanism (19) . However, the importance of the CSR in osmoregulation has been challenged. Lam et al. observed high urine osmolality and low urine volume in the presence of urine calcium concentrations greater than 5 mM/l (20) , and Bergsland et al. found no difference in urine volume in idiopathic hypercalciuric stone-formers as compared with controls, even though the hypercalciuric stone-formers had a twofold greater urine calcium excretion (21) . These observations suggest that urine calcium does not have a clinically significant role in osmoregulation. Diminished expression or responsiveness of the CSR in the CD could play a role in the pathogenesis of nephrocalcinosis, which has been reported to occur in up to 15% of premature infants (22) .
Clinical disorders of calcium homeostasis occur in premature infants through mechanisms that may involve the CSR, but no data are available regarding expression of the CSR in developing human kidney. Therefore, we studied CSR localization in developing human kidney between 20 and 40 wk of development using immunohistochemical methods.
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RESULTS
Sixteen autopsy cases in which death occurred between 20 and 40 wk gestation that met inclusion criteria were identified. Of these, seven fetuses died as a result of intrauterine demise, and nine infants died as a result of complications of prematurity. Extrauterine survival was ≤1 d in 7 cases and ≤8 d in 2 cases. Gender distribution was 14 males and 2 females. Interval from death to fixation averaged 19 h. The metanephric stage of kidney development was studied, which includes stage 3 (20-22 to 32-36 wk gestation) and stage 4 (which continues into adult life). Mature non-neoplastic renal tissue was obtained from five tumor nephrectomies to evaluate potential changes in expression of CSR between developing and mature kidneys. The age range was 7-67 y (mean 41 y), including three females and two males. Unless otherwise specified, the results and figures represent immunolocalization of the CSR using the monoclonal antibody clone 5C10. Because individual structures showed either diffusely positive or diffusely negative immunostaining for the CSR antibodies (both monoclonal and polyclonal antibodies), a semiquantitative approach to evaluate staining was not used.
CSR in Nephrogenic Zone
Nephrogenic structures could be reliably evaluated up to 32 wk gestational age in 13 cases; three cases represented 35 to 40 wk gestational age, when the nephrogenic zone is not present. There was no immunostaining for the CSR in either Wolffian duct-derived ureteric buds, or in metanephric blastemaderived early structures, including vesicle, C-shaped body, and early S-shaped body (Figure 1a,b) . Insets in Figure 1a ,b show the lack of CSR staining in ureteric bud and vesicle, and positive PAX2 nuclear staining in these structures, respectively.
Immunoreactivity for the CSR was first identified in the upper limb of the S-shaped body during early elongation of the upper limb at the stage of hemispheric cavity formation between the lower and upper limbs (Figure 1b) . At this stage of development, up to 14% of upper limbs showed weak cytoplasmic positivity for CSR. In more advanced stages of development, at the phase of Malpighian corpuscle formation, cytoplasmic CSR staining was present in approximately 80% of upper limbs. The cells of the upper limb differentiate into distinct distal tubule segments: macula densa (MD), distal convoluted tubule (DT), and ascending loops of Henle. CSR immunolocalization was observed in the same nephrogenic zone structures at 20 to 32 wk gestational age.
CSR in Developing and Mature Tubular Segments
Proximal tubule (PT) segments, including convoluted (S1) and straight segments (S2 and S3), did not demonstrate any CSR staining at any stage of development. The middle limb of the S-shaped body, which develops into PT, was also negative for CSR staining (Figure 1 a,b) .
In developing loops of Henle, weak CSR staining was noted in cells just proximal to the bend of the loop of Henle, representing the boundary between the descending and ascending limb epithelium (Figure 1a) . CSR was observed along the bend and in the TAL, MD, and DT. Within the medulla and renal papilla, large tubular structures representing CD were negative for CSR, whereas smaller loop of Henle tubules were positive for CSR and likely represent portions of the ascending limb in this stage of development ( Figure  2a,b) . Of note, the thin loop of Henle is distinguishable during fetal life only in the first few generations of nephrons and cannot be seen in older generations until after birth, 
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Articles remaining limited to descending limbs. Developing TAL and DT showed cytoplasmic and basolateral CSR staining of variable intensity with both CSR monoclonal and polyclonal antibodies (Figures 1 and 2) .
Mature human kidney tubular segments in the medulla showed immunolocalization of CSR limited to the TAL with both monoclonal and polyclonal antibodies tested (Figure 2c,d) . CSR expression was both cytoplasmic and membranous, with overall more intense basolateral staining when compared with the developing kidney. Cortical and medullary CD did not show immunoreactivity for CSR in principal epithelial cells or intercalated cells. Immunoreactivity of nephron segments throughout development and in mature human kidneys did not differ between the CSR monoclonal and polyclonal antibodies used.
Histomorphology and CSR in Developing Cortical Tubular Segments
Evaluation of CSR immunostaining in cortical and medullary tubular nephron segments was based on the histomorphologic characteristics of tissue sections stained with hematoxylin and eosin and the anatomic location of the tubules ( Figure  3) . Developing cortical tubule segments show differences in morphology as early as 20 wk gestational age. Proximal convoluted tubules (PT) are larger and more numerous compared with the short DT. PT are lined by cuboidal to low columnar cells with abundant eosinophilic granular cytoplasm; centrally located nuclei; and an apical, more eosinophilic brush border (Figure 3a,c) . DT show more nuclei per cross section, are lined by cuboidal cells with scant, pale to eosinophilic cytoplasm, apically located nuclei, and absent brush border (Figure 3a,c, inset in panel c) . TAL ascends into the cortex and bends over the glomerulus; the tubule segment abutting the glomerular vascular pole becomes the MD, and beyond the MD is the DT. All these distal tubule segments express CSR as seen in Figure 3b ,d. PT and glomeruli are negative for CSR.
Dual Immunohistochemistry
Dual immunohistochemistry studies were performed on four representative developing kidneys (gestational age: 20, Articles Crisi et al. 26 , 32, and 37 wk) and three mature kidneys to substantiate the morphologic interpretation. Dual stains were performed using the CSR monoclonal antibody and, in three mature kidney cases, using the polyclonal antibody.
CSR and CD10. Dual immunohistochemical studies were performed with antibodies to CSR (visualized by brown chromogen) and CD10 (visualized by red chromogen) to further evaluate CSR staining in PT. There was no colocalization of CD10 and CSR in proximal convoluted and straight tubules in developing kidney (Figure 4) . CD10-positive glomerular epithelial cells did not express CSR.
CSR and epithelial membrane antigen (EMA). Dual immunohistochemical studies were performed with antibodies to CSR (visualized by brown chromogen) and EMA (visualized by red chromogen) to further evaluate CSR localization in distal nephron segments, including TAL, DT, and cortical and medullary CD. CSR colocalized with EMA-positive TAL and DT in developing and mature human kidney (Figure 5) .
Throughout their length, EMA-positive cortical and medullary CD did not stain for CSR.
DISCUSSION
The data presented here demonstrate that the CSR is present in TAL and DT but is below the level of detection in other nephron segments in developing human kidney. Nephrogenic structures destined to form distal tubule segments are positive for the CSR, but other nephrogenic structures, including ureteric buds, are negative for CSR staining.
In fetal rat kidney, the CSR is expressed in apical epithelial cells of large tubules and branching ureteric buds. In the early postnatal period, there is a dramatic increase in expression of the CSR in rat kidney, principally in the TAL, but also in the CD (23) . In mature rat kidney, CSR expression in cortical CD is limited to intercalated cells (24) , whereas in inner medullary CD, the CSR is expressed in principal cells (18) . In the early stages of human renal development, immature and 
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Articles undifferentiated intercalated cells represent 3-4% of epithelial CD cells and are identified in the inner medulla CD, whereas later in gestation and postnatally, intercalated cells are present in outer medullary and cortical CD and account for 5-10% of CD cells (25) . We did not identify CSR localization throughout the CD during human renal development, nor did we identify CSR in other Wolffian duct-derived structures such as ureteric buds, which are positive for PAX2. A role for the CD CSR in preventing calcium stone disease, via enhanced free water excretion in response to increased urinary calcium, has been proposed (17) , but physiologic studies by Bergsland (21) and Lam (20) failed to demonstrate a change in urine volume induced by increased urinary calcium, observations that challenge the concept that the urinary calcium plays a role in regulation of urine volume. Because we did not observe staining for the CSR in developing CD, it is possible that absent or diminished CSR function in this developing nephron segment is a factor in the pathogenesis of nephrocalcinosis in these infants. Two studies have addressed localization of the CSR in mature human kidney. Using rabbit anti-CSR antiserum against bovine CSR (amino acids 215-237), Sands et al. demonstrated CSR staining of CD in frozen sections of human kidney (18) . In contrast, Loupe recently found that CSR staining of human kidney is limited to the TAL, using a mouse monoclonal antibody to amino acids 214-235 of the human CSR, as well as a polyclonal antibody directed against the C-terminal tail of the rat CSR (26) . We observed positive staining for the CSR in cells of the TAL, but not in cells of adjacent proximal tubule segments, and CD. This distinct pattern of CSR staining, in which CSR-positive tubules could be clearly distinguished from CSR-negative tubules, was noted as early as 20 wk of development, when active formation of nephrons Articles Crisi et al.
takes place in the subcapsular nephrogenic zone. CSR immunolocalization was observed in the same nephrogenic zone structures at 20 to 32 wk gestational age. Our observations suggest that functional differentiation of tubular cells is occurring at this stage in development. In the nephrogenic mesenchyme, we observed CSR immunolocalization in the upper limb of the S-shaped body, which is destined to develop into distal structures, including TAL and DT. Approximately 14% of S-shaped bodies at the stage of hemispheric cavity formation and approximately 80% of late S-shaped bodies demonstrated CSR staining in upper limb structures. Taken together, these observations suggest that CSR expression is a developmental phenomenon, occurring as these cells differentiate into their respective nephron components as nephrogenesis progresses.
PT did not stain for the CSR in developing human kidney. It has been suggested that aminoglycoside toxicity is mediated by the CSR via proximal tubular cell apoptosis (27) . Because many premature infants receive aminoglycosides as treatment for presumed sepsis, it is reassuring to note that we did not identify CSR expression in PT, which may explain the observation that acute aminoglycoside nephrotoxicity is an uncommon event in premature infants. In animal models, however, PT has been shown to express CSR (24) .
In our immunohistochemical studies of developing human kidney, the CSR was below the level of detection in PT and CD. However, immunohistologic studies have identified the CSR in these nephron segments in human as well as animal kidney, and physiologic studies of cells from these regions document functions attributable to this receptor. There are a number of reasons that may explain the lack of immunolocalization of CSR in these developing nephron segments. At this stage in human development, the CSR may not be expressed in immature or undifferentiated tubular cells, including intercalated cells, in these developing nephron segments. Alternatively, the CSR may be present in developing PT and CD at a very low density on the cell membrane when compared with cells of the TAL, but still capable of physiologic response. The membrane density of this receptor may increase as a normal developmental sequence or in response to changes in peritubular or luminal calcium concentration. In the work presented, using both monoclonal and polyclonal CSR antibodies, CSR protein expression in developing human CD and PT is either absent or below the detection limits of immunohistochemistry with the antibodies used in this study. It is possible that regardless of antigen retrieval, in formalin-fixed tissue, the targeted epitopes of the antibodies used may not be available in PT or CD for antigen-antibody interaction and therefore not detected by immunohistochemical methods. To obtain answers to these questions, studies of developing human CD and PT using more sensitive techniques are required. We could not confidently utilize in situ hybridization in our study of archival formalin-fixed, paraffin-embedded renal tissue because of RNA degradation.
The role of the renal CSR during fetal development has been studied. Mice targeted for deletion of the CSR die soon after birth because of severe hyperparathyroidism and hypercalcemia (28) , whereas mice deficient in both the CSR and parathyroid hormone develop normally, suggesting that the deleterious effects of CSR gene deletion on the fetus are caused by hyperparathyroidism and hypercalcemia (29) . Kovacs et al. found that amniotic fluid calcium concentration in mice lacking the CSR gene is elevated in comparison to normal mice, reflecting the relative hyperparathyroidism or hypercalcemia. Furthermore, these authors found that amniotic fluid calcium was similar in mice heterozygous and homozygous for deletion of the CSR, and speculated that fetal tubular handling of calcium is not affected by CSR gene disruption (30) .
The CSR may play a role in preventing calcium-related disorders in premature infants. In the newborn period, hypercalcemia is uncommon, occurring in association with idiopathic infantile hypercalcemia and primary or secondary hyperparathyroidism; iatrogenic hypercalcemia may be the most common cause (31) . Loss-of-function mutations of the CSR gene are associated with hypocalciuria and hypercalcemia. Given that hypercalcemia is rare in the newborn period, it is likely that the CSR, expressed in the TAL, participates in calcium homeostasis during early development by increasing urinary calcium excretion in response to elevated serum calcium. Nephrocalcinosis has been reported to occur in about 15% of premature infants and may also occur in association with gain-of-function mutations of the CSR, which are characterized by hypocalcemia and hypercalciuria. It is possible to speculate that impaired regulation of CSR function in the TAL, leading to an exaggerated response to serum calcium and increased urinary calcium excretion, could play a role in the development of nephrocalcinosis in premature infants. Because the CSR is not expressed in the CD at any point in development, and because recent data fail to demonstrate a role for calcium in osmoregulation, it is unlikely that the CSR plays a role in nephrocalcinosis via dilution of urine in response to increased calcium.
In summary, the CSR is present in the developing human kidney in TAL and DT, as well as in early nephrogenic structures destined to form these nephron segments. The CSR could not be detected in developing proximal tubule segments and CD, nor in nephrogenic structures destined to form these nephron segments. Presence of the CSR is characteristic of developing human TAL, where this receptor may play a role in renal calcium regulation in premature infants.
METHODS
This study was based on archival autopsy material and was approved by the institutional review board of Baystate Medical Center. The renal tissue studied was obtained after death as a result of intrauterine spontaneous fetal demise, or from infants who died as a result of the complications of prematurity. A search of the pathology CoPath electronic files was performed for autopsies between 20 and 40 wk of intrauterine development. All tissues were archival formalin-fixed and paraffin-embedded tissue blocks. Hematoxylin and eosin-stained kidney tissue sections were reviewed to evaluate for adequacy of tissue preservation and for presence of an intact renal capsule. Exclusion criteria included genetic abnormalities (based on cytogenetic testing or morphology) and inadequate preservation of renal histomorphology. Mature non-neoplastic renal tissue was obtained from five tumor nephrectomies.
